Michael Gelband’s Lineage Cell Therapeutics LCTX Stock Holding History

Michael Gelband’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,157	Closed	-$33.4K	–	1841
2026 Q1	$33.4K	Sell	21,157 -160,537	-88%	-$271K	﹤0.01%	1467
2025 Q4	$303K	Buy	+181,694	New	+$314K	﹤0.01%	1310
2025 Q3	–	Sell	-19,149	Closed	-$17K	–	1796
2025 Q2	$17K	Buy	+19,149	New	+$11.4K	﹤0.01%	1387
2023 Q2	–	Sell	-32,143	Closed	-$48K	–	2072
2023 Q1	$48K	Buy	+32,143	New	+$44.9K	﹤0.01%	1667
2022 Q1	–	Sell	-12,142	Closed	-$30K	–	2454
2021 Q4	$30K	Buy	+12,142	New	+$28.4K	﹤0.01%	2069
2021 Q2	–	Sell	-334,197	Closed	-$785K	–	2599
2021 Q1	$785K	Sell	334,197 -473,415	-59%	-$1.14M	0.01%	1064
2020 Q4	$1.42M	Buy	807,612 +792,095	+5,105%	+$1.11M	0.01%	688
2020 Q3	$15K	Buy	15,517 +2,293	+17%	+$2.02K	﹤0.01%	1673
2020 Q2	$12K	Buy	+13,224	New	+$11.6K	﹤0.01%	1715

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Michael Gelband's LCTX Position: Q2 2026 in Review

Michael Gelband sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 21,157 shares — an estimated $33.4K sold.

Michael Gelband first reported a position in LCTX in Q2 2020 and held it in 9 quarters. The position peaked at $1.42M in Q4 2020. 131 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Michael Gelband reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 21,157 Lineage Cell Therapeutics shares in Q2 2026, an estimated $33.4K.
Michael Gelband first reported a position in Lineage Cell Therapeutics in Q2 2020 and held it in 9 quarters.
Michael Gelband's Lineage Cell Therapeutics position peaked at $1.42M in Q4 2020.
131 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.